Original Research Manuscript

Title

Examination of Medication Use Patterns by Age Group, Comorbidity, and Month in COVID-19 Positive Patients in a Large State-wide Health System During the Pandemic in 2020.

Authors in Order:

Jonathan H. Watanabe, PharmD, PhD (Corresponding Author)
Associate Dean of Assessment and Quality
Professor of Clinical Pharmacy
Department of Clinical Pharmacy Practice
UC Irvine School of Pharmacy & Pharmaceutical Sciences
101 Theory, Suite 100
Irvine, CA 92697
949-824-0498
jonathan.watanabe@uci.edu

Jimmy Kwon, MS
Department of Statistics
UC Irvine Donald Bren School of Information and Computer Sciences
Irvine, CA 92697

Bin Nan, PhD
Professor
Department of Statistics
UC Irvine Donald Bren School of Information and Computer Sciences
Irvine, CA 92697

Shira R. Abeles, MD
Medical Program Director of Antimicrobial Stewardship
Associate Medical Program Director of Infection Prevention and Clinical Epidemiology
Assistant Clinical Professor
Department of Medicine
UC San Diego School of Medicine
La Jolla, CA 92093

Sanjay R. Mehta, MD
Acting Head of the Infectious Disease Section, VA San Diego
Director of the VA San Diego Clinical Microbiology Laboratory
Associate Clinical Professor
Department of Medicine
UC San Diego School of Medicine
La Jolla, CA 92093

Manuscript Word Count: 2895

Abstract

Objectives:

Main objective was to systematically determine most frequently used medications among COVID-19 patients overall and by hospitalization status. Secondary objective was to measure use patterns of medications considered potential therapeutic options

Design: Retrospective cohort study.

Setting: The five academic medical centers of University of California Health.

Participants: University of California COVID Research Data Set (UC CORDS) patients between March 10, 2020 and December 31, 2020.

Exposure(s): Confirmed COVID-19 positive by SARS-CoV-2 nucleic acid amplification.

Main Outcome(s) and Measure(s): Main outcomes were percentages of patients prescribed medications, overall, by age group, and by comorbidity based on hospitalization status. Use percentage by month of COVID-19 diagnosis was measured. Cumulative count of potential therapeutic options was measured over time.

Results:

Dataset included 22897 unique patients with COVID-19 (mean [SD] age, 42.4 [20.4] years; 12154 [53%] female). Among the sample, 6326 (28%) were non-Hispanic White, 8475 (37%) were Hispanic, 1562 (7%) Asian, and 1313 (6%) Black. A COVID-related hospitalization occurred in 3546 patients. Of the hospitalized patients, more than 30% had baseline comorbidities of hypertension (48%), hyperlipidemia (37%), and type 2 diabetes (35%). Most frequently used medications in patients overall were acetaminophen (21.2%), albuterol (14.9%), ondansetron (13.9%), and enoxaparin (10.8%). Medications used were generally similar across ages and comorbidities. Prior to May, dexamethasone was rarely used, with well under 50 COVID-19 patients that had been hospitalized to that point receiving the medication. By mid-August, more than 500 patients to that point had received dexamethasone. Hydroxychloroquine use effectively halted in COVID-19 hospitalized patients after May. Throughout the period of March to December 2020, enoxaparin was used in the most patients to that point at any instance. By mid-December, more than 2000 in the analysis cohort of hospitalized patients had received enoxaparin.

Conclusions and Relevance:

In this retrospective cohort study, across age and comorbidity groups, predominant utilization was for supportive care therapy. Dexamethasone and remdesivir experienced large increases in use. Conversely, hydroxychloroquine and azithromycin use markedly dropped. Medication utilization rapidly shifted towards more evidence-concordant treatment of patients with COVID-19 as rigorous study findings emerged.

Introduction

Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Awareness of the SARS-CoV-2 infectious capacity coupled with a case fatality rate greater than 0.6%¹ has led to global efforts to reduce transmission and identify effective treatment approaches. As of July 9, 2021 there have been more than 185 million confirmed cases and in excess of 4 million deaths worldwide.²

Understanding medication use patterns for patients with confirmed COVID-19 will provide needed insight into the evolution of COVID-19 treatment over the course of the SARS-CoV-2 Pandemic and provide evidence for clinical management considerations. The goal for this analysis was to characterize the frequency of medications used based on percentage of COVID-19 positive individuals receiving the medications overall, by age group, and by comorbid condition for both hospitalized and non-hospitalized patients. To examine how this pattern has changed since the pandemic began, medication use based on month of diagnosis was tracked. To quantify use of medications considered as possible treatments that impact the clinical course by shortening the duration of symptoms or preventing complications (referred hereafter as ‘potential therapeutic options’), dexamethasone, remdesivir, enoxaparin, heparin, colchicine, hydrocortisone, tocilizumab, azithromycin, hydroxychloroquine and medication classes of angiotensin-2 converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs),^{3–9} number of hospitalized patients in the cohort that used each PTO were counted over the pandemic.

Methods

The University of California COVID Research Data Set (UC CORDS) was constructed to be a timely data set for research purposes distributed weekly, containing SARS-CoV-2 testing results and COVID-19 treatment information collected from across University of California (UC) Health. It is a Health Insurance Portability and Accountability Act (HIPAA) Limited Data Set generated from all five UC Health medical centers (Davis, Irvine, Los Angeles, San Diego, San Francisco). In 2019, UC Health had 1,092,522 inpatient days. This was equivalent to 6.6% of the total inpatient days in the state. Care was provided to 1.8 million unique patients by UC Health in 2019 which is 4.6% of the population of California that year.^{10–12} UC CORDS was operationalized by UC Health as ‘non-human subjects research’ and analyses are considered institutional review board exempt. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline was followed for this analysis.¹³

Data for 22897 patients confirmed positive with COVID-19 by SARS-CoV-2 RNA nucleic acid amplification with probe detection was extracted for the period of March 10, 2020 through December 31, 2020. Consistent with UC Health reporting, patients were categorized as experiencing a COVID-19-related hospitalization if they were admitted to the hospital within 30 days of confirmed test or tested positive during their hospitalization.

Generation of Comorbidities from EHRs

Patients with COVID-19 with comorbid conditions of hypertension, hyperlipidemia, type 2 diabetes, COPD/Asthma, heart disease, chronic kidney disease (CKD), cancer, obesity, the respiratory diseases asthma and COPD, and those receiving dialysis are at increased risk for poor outcomes.^{14–16} To examine medication utilization in patients diagnosed with COVID-19 with these risk factors at baseline, we first determined the presence of these conditions using the *International Classification of Diseases, Tenth Revision, Clinical Modification* (ICD-10-CM) codes in the patient electronic health record (EHR). Given the possibility that preexisting conditions would not be reported at COVID-19 diagnosis, ICD-10-CM codes up to one-year preceding diagnosis were included. Self-reported gender and race/ethnicity were extracted from EHR as well as body mass index (BMI) for hospitalized patients. Age was estimated based on patient birth year as

birthdate was removed from UC CORDS for de-identification. Uses of mechanical ventilation and extracorporeal membrane oxygen (ECMO) were extracted for each hospitalized patient using affiliated *International Classification of Diseases, Tenth Revision, Procedure Coding System* codes and Current Procedural Terminology, 4th Edition codes.

Medications used for each patient were determined from the EHR by measurement of all medication active ingredients utilized within 30 days of COVID-19 positive test based on the RxNorm standardized nomenclature for clinical drugs from the National Library of Medicine.¹⁷ Given the assumption, in context of COVID-19, of a similar therapeutic class effect of angiotensin converting enzyme-2 inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) usage of these medications was collapsed to the overall category of 'ACEIs/ARBs'. Monthly utilization was based on month in which patient was confirmed for COVID-19.

Statistical Analysis

Descriptive measurement of demographic and clinical characteristics was performed for COVID-19 positive patients in the sample overall and by hospitalization status. Continuous data were expressed as mean +/- SD or median and interquartile range [IQR] values. Use was quantified by percentage of patients with corresponding 95% confidence interval. All confidence intervals and subgroup sample sizes are included in the affiliated tables.

Data were extracted with module pyodbc, version 4.0.30 in Python, version 3.8.3 (Python Software Foundation). All analyses performed in R, version 3.6.3 (R Project for Statistical Computing). Statistical significance defined using two-sided significance level of alpha = 0.05.

Results

Descriptive Statistics

The dataset contained 22897 unique patients confirmed positive for COVID-19 between March 10, 2020 and December 31, 2020 (mean [SD] age, 42.4 [20.4] years; 12154 [53%] female; median [25th, 75th percentile] BMI for hospitalized patients, 28.5 [23.8, 32.9]. Among the sample, 6326 (28%) were non-Hispanic White, 8475 (37%) were Hispanic, 850 (7%) Asian, 738 (6%) Black and 6013 (47%) reported as 'other'. Of the 22897 unique COVID-19 test confirmed patients, 2584 patients had a COVID-related hospitalization. Of the hospitalized patients, the most common comorbidity was hypertension (48%). Greater than 20% of hospitalized patients had hyperlipidemia (37%), type 2 diabetes (35%), heart disease (24%), and CKD (22%). The rates of Asthma/COPD and cancer in hospitalized patients were 17% and 13%, respectively (Table 1).

Medication utilization overall and for patients by hospitalization status by age group, comorbidity, hospital procedure status

All Patients that Tested Positive for COVID-19

The ten medications used in the largest percentage of confirmed COVID-19 patients over the study period overall were acetaminophen (21.2%), albuterol (14.9%), ondansetron (13.9%), enoxaparin (10.8%), sennosides (9.3%), lidocaine (8.5%), polyethylene glycol (PEG) 3350 (8.4%), dexamethasone 8.1%, azithromycin (7%), insulin lispro (6.8%). Acetaminophen, ondansetron, albuterol, enoxaparin, and sennosides were part of the top five medications for every age category except for those under 50 years old where lidocaine was present rather than sennosides (Table 2). Across

comorbidities, medications were consistent with those observed in the age group analysis. For any of the baseline comorbidities, the medication used in the largest proportion was acetaminophen. Usage of acetaminophen ranged from 39.6% in patients with Cancer to 61.5% for patients with CKD. Enoxaparin or heparin was a top ten medication for all comorbidities. For patients that received dialysis at baseline, most frequent medications were acetaminophen, heparin, insulin lispro, ondansetron, lidocaine, sennosides, albuterol, pantoprazole, vancomycin, and PEG 3350 (Table 3).

Hospitalized Patients with COVID-19

The ten medications used in the largest percentage of confirmed COVID-19 hospitalized patients were acetaminophen (88.6%), enoxaparin (62.1%), ondansetron (59%), sennosides (54.1%), albuterol (53.3%), PEG 3350 (49.2%), lidocaine (42.5%), dexamethasone (40.1%), heparin (38.8%), insulin lispro (38.4%). Medications were similar across age groups. Dexamethasone was among the top ten medications for all age groups (Table 2). Heparin was among the top ten for all comorbidities except for COPD/Asthma. For patients that received dialysis at baseline, top medications were heparin, acetaminophen, insulin lispro, lidocaine, sennosides, vancomycin, ondansetron, albuterol, pantoprazole, and PEG 3350. For obese patients, the medications in the top ten were consistent with the overall list for hospitalized patients (Table 3).

For hospitalized COVID-19 patients that had mechanical ventilation, top medications were acetaminophen, fentanyl, sennosides, PEG 3350, furosemide, propofol, heparin, vancomycin, lidocaine, and albuterol. For patients that received ECMO, top medications were fentanyl, heparin, furosemide, sennosides, albumin, vancomycin, dexmedetomidine, PEG 3350, propofol, and midazolam (Table 3).

Non-Hospitalized Patients with COVID-19

The proportion of individuals receiving each medication was substantially lower in non-hospitalized patients. The ten medications used in the most patients were acetaminophen (8.8%), albuterol (7.8%), ondansetron (5.7%), azithromycin (3.7%), ACEIs/ARBs (3.6%), benzonatate (3.2%), ibuprofen (2.8%), fluticasone (2.7%), atorvastatin (2.5%), and guaifenesin (2.3%). Among all age groups, acetaminophen was the most common ranging from 7.4% in those under 50 years old to 13.4% for those 65 years old and above. Albuterol and ondansetron were among the top ten for all age groups (Table 2). For all comorbidities studied, ACEIs/ARBs were among the six most commonly used medications and were the first or second most common for hypertension (19.1%), hyperlipidemia (13.3%), type 2 diabetes (18.3%), heart disease (16.4%), and CKD (16.4%). Ondansetron was among the ten most commonly used medications for all comorbidities. For patients that had baseline dialysis, top medications were acetaminophen, heparin, atorvastatin, ondansetron, albuterol, carvedilol, sevelamer, insulin lispro, pantoprazole, albumin (Table 3).

Medication utilization by month of COVID-19 diagnosis

All patients that tested positive for COVID-19

In March, among all patients COVID-19 test confirmed, the most common medications were acetaminophen (21.3%), albuterol (20.5%), azithromycin (16.2%), ondansetron (12.5%), guaifenesin (11.7%), enoxaparin (11.2%), PEG 3350 (10.5%), hydroxychloroquine (10.2%), ceftriaxone (9.6%), and sennosides (9.6%). By April, while the most common medications were similar, use of azithromycin and hydroxychloroquine dropped. Consequently, March was the only month in which hydroxychloroquine appeared among the top ten. April was the last month in which ceftriaxone was among the top ten. Enoxaparin was the sixth most commonly used medication in March at 11.2%, but increased in May to the third most used medication at 22.8%. Enoxaparin remained in the top five medications through December.

Dexamethasone was observed as a top ten medication for the first time in July (8.3% of patients), increasing to 11.1% in August, and remained among the top eight prescribed meds thereafter. Heparin was not among the top ten medications after September (Table 4).

Hospitalized Patients with COVID-19

In March, the most common medications for those hospitalized were acetaminophen (85.8%), enoxaparin (56.6%), albuterol 56.6%, azithromycin (54%), PEG 3350 (51.3%), ondansetron (48.7%), ceftriaxone (48.7%), guaifenesin (47.8%), sennosides (45.1%), and hydroxychloroquine (43.4%). The top two medications were acetaminophen and either enoxaparin or ondansetron for every month. From March to April, azithromycin use dropped from 54% to 40.5%. Hydroxychloroquine declined rapidly from a high of 43.4% in March and was not in the ten most common medications for the duration of the study. Early in the Pandemic, ceftriaxone was frequently used (48.7% and 45.9% of patients in March and April, respectively). After April, however, ceftriaxone was no longer found among the ten most frequently used medications. Heparin was not among the top ten medications after September. Dexamethasone was used in 43.3% of patients in July with usage exceeding 50% in November and December. Remdesivir, approved under FDA emergency use authorization in May 2020, was among the top ten medications in October at 39.9% and increased to 52.7% in December (Table 4).

Non-Hospitalized Patients with COVID-19

In March, the top medications were albuterol (11.9%), azithromycin (7.3%), acetaminophen (6.1%), ACEIs/ARBs (4.8%), ondansetron (4%), codeine (4%), benzonatate (3.8%), guaifenesin (3.1%), fluticasone (2.9%), atorvastatin (2.9%). While azithromycin use decreased after March, it remained among the top ten in all months except August and September. Albuterol and acetaminophen were among the top three medications throughout. Fluticasone was among the top ten medications in all months besides October and December. Dexamethasone was among the top ten medications from August through December (Table 4).

Cumulative Use Count in Hospitalized Patients Since March 2020 of Potential Treatment Option Medications in Hospitalized Patients

Throughout the period of March to December 2020, enoxaparin was used in the most patients to that point at any instance. By mid-December, more than 2000 in the analysis cohort of hospitalized patients had received enoxaparin. Prior to May, dexamethasone was rarely used, with well under 50 COVID-19 patients that had been hospitalized to that point receiving the medication. By mid-August, more than 500 patients to that point had received dexamethasone. By mid-December, dexamethasone use increased to the extent that more than 1000 patients to that point had received it. Hydroxychloroquine use effectively halted in COVID-19 hospitalized patients after May. Azithromycin prescribing slowed from initial heavy use. Among the PTOs studied, it was the third most frequently used in patients as of August 1, but by close of 2020 had fallen to the sixth most commonly used. Increase in counts of heparin, ACEIs/ARBs, and hydrocortisone use was fairly stable over time. Total dexamethasone users exceeded azithromycin users by end of August. Roughly 1000 patients had received remdesivir by close of December (Figure 1).

Discussion

This study is the first comprehensive analysis of medication utilization for COVID-19 patients in a large, diverse, state-wide health system overall and by comorbidity, age group, baseline dialysis use, and by month for both the hospitalized and non-hospitalized. Numbers of patients that used medications considered potential therapeutic options during the Pandemic were also tracked over time.

Initially, in the Pandemic, our data shows attempts were made to use antimicrobials to manage COVID-19. Azithromycin, ceftriaxone, and hydroxychloroquine were each used in more than 40% of hospitalized patients in March. This quickly abated. By May, none of the three were amongst the top ten medications for hospitalized patients. Supportive care medications for symptom relief of fever, nausea, pain, cough, constipation, and shortness of breath were heavily used throughout with acetaminophen being used in the largest percentage of all COVID-19 patients followed by albuterol, ondansetron, enoxaparin, and sennosides. Enoxaparin had over 50% use throughout 2020 as enoxaparin serves both as supportive care for deep vein thrombosis prophylaxis and for treatment, given the thrombophilia caused by COVID-19.¹⁹ Examining other potential therapeutic option over time, dexamethasone and remdesivir use increased substantially. Use of remdesivir likely corresponded with availability, as early in the Pandemic, it was only available through trials. On the other hand, hydroxychloroquine use dropped from over 40% in late March and was not observed in top ten medications beyond that month. Early studies of limited sampled size favored use of these agents,^{20,21} but later larger, controlled studies did not demonstrate clinical benefit in patients.^{7,22}

Treatment for COVID-19 patients has progressed from the initial stages, where treatment decisions were educated based on case series and in vitro data. With little guidance, the early approaches applied by clinicians were best guesses. Remarkably, practice patterns appeared to change in near real-time as quality data became available through landmark trials. The trajectories of medication usage generally corresponded to publication of rigorous studies. The acceleration in use of dexamethasone is reasonably correlated to the publication of findings from the RECOVERY trial.³ The wide accessibility of data, effectively at the moment of publication, to clinicians over the course of the Pandemic is unparalleled compared to past public health crises. This was demonstrated by the potential therapeutic option curves where usage was generally concordant with the emerging evidence over time. A prior study examined outpatient prescriptions for hydroxychloroquine noted a decline after May 2020. However, this analysis was not focused on patients confirmed for COVID-19.²³ An analysis over a two month period that examined medication use patterns in COVID-19 hospitalized patients also showed reductions in azithromycin and hydroxychloroquine over time.²⁴ Differentiating strengths of our study compared to these prior studies was a longer duration (March to December 2020) to observe oscillations in use of these agents. Beyond a small selection of medications, we captured use patterns of the most common medications prescribed by age, high-risk condition, and month.

Overall, this analysis also demonstrated that most of the medications used to treat COVID-19 patients have been generally inexpensive, generic medications. While this is comforting, more expensive proprietary medications have now been released under EUA (e.g. monoclonal antibodies). Furthermore, generic medications have been increasingly subject to shortages. This compilation of medication use from the COVID-19 experience can serve as a guide for medication needs during future pandemics from respiratory viruses.

The population of COVID-19 patients in the CORDS features a demographic breakdown consistent overall with the State of California. Hispanics were 37% of the study population which is similar to 39% of the state. Non-Hispanic Whites were 28% of COVID-19 positive patients in this study population compared to 37% in the state. Percentages of those in the sample that reported to be Black, and Native Hawaiian/Pacific Islander/American Indian/Alaska Native were similar to the demographic breakdown of California (7% and 1%, respectively).¹²

Limitations

Outpatient medications for patients in CORDS may require at least a month for complete capture. Use rates are conservative estimates for the non-hospitalized patients since medications for COVID-19 positive patients prescribed medications outside of UC Health are not present in CORDS. While the study demographics were consistent with California overall, given, that this state has a large minority population this may influence generalizability to the US. Consequently, the percentage of COVID-19 positive cases that were Non-Hispanic White in CORDS (28%) was lower than

that observed in US national estimates (56%). Hispanics were 37% of the positive cases in our dataset and 21% in the US. A smaller percentage of COVID-19 positive patients were black (6%) than observed in national estimates (12.2%). Asians were 7% of the COVID-19 positive patients in CORDS compared to 4% in US estimates.²⁵

Conclusions

In this retrospective cohort study, across age and comorbidity groups, predominant utilization was for supportive care therapy. Dexamethasone and remdesivir experienced large increases in utilization over time. Conversely, hydroxychloroquine and azithromycin use rapidly declined. Anticoagulation was recognized early in the Pandemic as an important approach for both prophylaxis and in treatment and was widely applied throughout. Medication utilization has changed, in near real-time, in the direction of evidence-concordant treatment of patients with COVID-19 as quality data became available.

References

1. Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. *Int J Infect Dis*. 2020;101:138-148. doi:10.1016/j.ijid.2020.09.1464
2. COVID-19 Map. Johns Hopkins Coronavirus Resource Center. Accessed November 8, 2020. <https://coronavirus.jhu.edu/map.html>
3. Group TRC. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. *N Engl J Med*. doi:10.1056/NEJMoa2021436
4. Barco S, Bingisser R, Colucci G, et al. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. *Trials*. 2020;21(1):770. doi:10.1186/s13063-020-04678-4
5. Thachil J. The versatile heparin in COVID-19. *J Thromb Haemost*. 2020;18(5):1020-1022. doi:<https://doi.org/10.1111/jth.14821>
6. Devereux SG, Giannopoulos G, Vrachatis DA, et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. *JAMA Netw Open*. 2020;3(6):e2013136. doi:10.1001/jamanetworkopen.2020.13136
7. Group TRC. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med*. Published online October 8, 2020. doi:10.1056/NEJMoa2022926
8. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. *N Engl J Med*. 2020;0(0):null. doi:10.1056/NEJMoa2028836
9. Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. *JAMA Cardiol*. 2020;5(7):825. doi:10.1001/jamacardio.2020.1624
10. Medical Centers Report 19/20. :121.
11. FastStats. Published June 19, 2019. Accessed July 2, 2019. <https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm>
12. U.S. Census Bureau QuickFacts: California. Accessed February 24, 2021. <https://www.census.gov/quickfacts/CA>
13. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. *Ann Intern Med*. 2007;147(8):573-577. doi:10.7326/0003-4819-147-8-200710160-00010
14. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3

15. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *The Lancet*. 2020;395(10239):1763-1770. doi:10.1016/S0140-6736(20)31189-2
16. Ng JH, Hirsch JS, Wanchoo R, et al. Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. *Kidney Int*. 2020;98(6):1530-1539. doi:10.1016/j.kint.2020.07.030
17. RxNorm Technical Documentation. Accessed November 12, 2020. https://www.nlm.nih.gov/research/umls/rxnorm/docs/techdoc.html#s1_0
18. James G, Witten D, Hastie T, Tibshirani R. *An Introduction to Statistical Learning*. Vol 103. Springer New York; 2013. doi:10.1007/978-1-4614-7138-7
19. Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. *J Thromb Haemost*. 2020;18(4):786-787. doi:10.1111/jth.14781
20. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *medRxiv*. Published online April 10, 2020:2020.03.22.20040758. doi:10.1101/2020.03.22.20040758
21. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020;56(1):105949. doi:10.1016/j.ijantimicag.2020.105949
22. Self WH, Semler MW, Leither LM, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. *JAMA*. 2020;324(21):2165-2176. doi:10.1001/jama.2020.22240
23. Bull-Otterson L, Gray EB, Budnitz DS, et al. Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment — United States, January–June 2020. *Morb Mortal Wkly Rep*. 2020;69(35):1210-1215. doi:10.15585/mmwr.mm6935a4
24. Lin KJ, Schneeweiss S, Tesfaye H, et al. Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity. *Drugs*. 2020;80(18):1961-1972. doi:10.1007/s40265-020-01424-7
25. CDC. COVID Data Tracker. Centers for Disease Control and Prevention. Published March 28, 2020. Accessed February 21, 2021. <https://covid.cdc.gov/covid-data-tracker>

Figure 1. Cumulative Count of Hospitalized Patients Using Potential Therapeutic Option Over Time

Table 1. Descriptive Characteristics of the COVID-19 Test Confirmed Patients

	Tested COVID-19 Positive n(%)	Non-Hospitalized n(%)	Hospitalized n(%)
Age			
Sample Size	22897	19351	3546
mean (sd)	42.35 ± 20.40	39.92 ± 19.35	55.63 ± 20.84
under 50	14,379 (63)	13,121 (68)	1,258 (35)
50 to <65	4,985 (22)	4,014 (21)	971 (27)
65 or older	3,533 (15)	2,216 (11)	1,317 (37)
Gender			
Female	12,154 (53)	10,573 (55)	1,581 (45)
Race & Ethnicity			
non-Hispanic White	6,326 (28)	5,417 (28)	910 (26)
Hispanic	8,475 (37)	6,768 (35)	1,707 (48)
Black	1,313 (6)	1,041 (5)	272 (8)
Asian	1,562 (7)	1,262 (7)	300 (8)
Native Hawaiian / Other Pacific Islander / American Indian / Alaska Native	252 (1)	200 (1)	52 (1)
Other	3,100 (14)	2,378 (12)	722 (20)
Not Reported	7,012 (31)	6,316 (33)	696 (20)
Body Mass Index of Hospitalized Patients			
median (25th, 75th)	NA	NA	28.5 (23.8, 32.9)
< 18.5	NA	NA	98 (3)
18.5 to < 25.0	NA	NA	849 (26)
25 to < 30.0	NA	NA	1,004 (30)
30 or more	NA	NA	1,364 (38)
Variable			
Hypertension	4,200 (18)	2,503 (13)	1,697 (48)
Hyperlipidemia	3,721 (16)	2,411 (12)	1,310 (37)
Type 2 Diabetes	2,685 (12)	1,427 (7)	1,258 (35)
Asthma/COPD	1,795 (8)	1,198 (6)	597 (17)
Heart Disease	1,520 (7)	670 (3)	850 (24)
Chronic Kidney Disease	1,326 (6)	548 (3)	778 (22)
Cancer	1,394 (6)	921 (5)	473 (13)
Baseline Dialysis	190 (1)	46 (0)	144 (4)
Hospital Procedures			
Mechanical Ventilation	661 (3)	0 (0)	661 (19)
ECMO	54 (0)	0 (0)	54 (2)
Positive Covid Test Month			
March	591 (3)	478 (2)	113 (3)
April	921 (4)	699 (4)	222 (6)
May	709 (3)	467 (2)	242 (7)
June	1,915 (8)	1,542 (8)	373 (11)
July	3,789 (17)	3,202 (17)	587 (17)
August	2,027 (9)	1,617 (8)	410 (12)
September	1,108 (5)	863 (4)	245 (7)
October	1,083 (5)	880 (5)	203 (6)
November	3,200 (14)	2,872 (15)	328 (9)
December	7,554 (33)	6,731 (35)	823 (23)

Table 2. Medication Utilization by Age Group

All Positive COVID-19 Patients

Rank	Overall (n = 22896)	Percent	95% CI	<50 (n = 14379)	Percent	95% CI	50 to <65 (n = 4984)	Percent	95% CI	65 or older (n = 3533)	Percent	95% CI
1	acetaminophen	21.2	(20.6, 21.7)	acetaminophen	14.3	(13.7, 14.9)	acetaminophen	26.2	(25.0, 27.4)	acetaminophen	41.8	(40.2, 43.4)
2	albuterol	14.9	(14.4, 15.3)	albuterol	9.4	(8.9, 9.9)	albuterol	20.7	(19.6, 21.8)	albuterol	28.8	(27.3, 30.3)
3	ondansetron	13.9	(13.5, 14.4)	ondansetron	9.4	(8.9, 9.9)	ondansetron	17.6	(16.5, 18.7)	ondansetron	27.1	(25.6, 28.6)
4	enoxaparin	10.8	(10.4, 11.2)	enoxaparin	5.6	(5.2, 6.0)	enoxaparin	15.5	(14.5, 16.5)	sennosides, USP	25.8	(24.4, 27.2)
5	sennosides, USP	9.3	(8.9, 9.7)	lidocaine	5.4	(5.0, 5.8)	sennosides, USP	12.4	(11.5, 13.3)	enoxaparin	25.3	(23.9, 26.7)
6	lidocaine	8.5	(8.1, 8.9)	ibuprofen	5.0	(4.6, 5.4)	dexamethasone	11.7	(10.8, 12.6)	polyethylene glycol 3350	23.2	(21.8, 24.6)
7	polyethylene glycol 3350	8.4	(8.1, 8.8)	sennosides, USP	4.2	(3.9, 4.5)	ACEIs/ARBs	11.2	(10.3, 12.1)	atorvastatin	21.3	(19.9, 22.7)
8	dexamethasone	8.1	(7.8, 8.5)	polyethylene glycol 3350	4.0	(3.7, 4.3)	insulin lispro	11.0	(10.1, 11.9)	dexamethasone	20.3	(19.0, 21.6)
9	azithromycin	7.0	(6.6, 7.3)	azithromycin	4.0	(3.7, 4.3)	polyethylene glycol 3350	10.8	(9.9, 11.7)	ACEIs/ARBs	19.1	(17.8, 20.4)
10	insulin lispro	6.8	(6.5, 7.1)	benzonatate	4.0	(3.7, 4.3)	benzonatate	10.7	(9.8, 11.6)	heparin	19.0	(17.7, 20.3)

Hospitalized Patients

Rank	Overall(n = 3545)	Percent	95% CI	<50(n = 1258)	Percent	95% CI	50 to <65(n = 970)	Percent	95% CI	65 or older(n = 1317)	Percent	95% CI
1	acetaminophen	88.6	(87.6, 89.7)	acetaminophen	86.8	(84.9, 88.7)	acetaminophen	89.6	(87.7, 91.5)	acetaminophen	89.6	(87.9, 91.3)
2	enoxaparin	62.1	(60.5, 63.7)	ondansetron	61.9	(59.2, 64.6)	enoxaparin	70.6	(67.7, 73.5)	sennosides, USP	63.0	(60.4, 65.6)
3	ondansetron	59.0	(57.4, 60.6)	enoxaparin	56.6	(53.9, 59.3)	albuterol	62.2	(59.1, 65.3)	enoxaparin	61.2	(58.6, 63.8)
4	sennosides, USP	54.1	(52.4, 55.7)	sennosides, USP	43.2	(40.5, 45.9)	ondansetron	59.2	(56.1, 62.3)	albuterol	58.2	(55.5, 60.9)
5	albuterol	53.3	(51.7, 55.0)	lidocaine	42.8	(40.1, 45.5)	sennosides, USP	56.1	(53.0, 59.2)	polyethylene glycol 3350	57.5	(54.8, 60.2)
6	polyethylene glycol 3350	49.2	(47.5, 50.8)	albuterol	41.3	(38.6, 44.0)	polyethylene glycol 3350	49.0	(45.9, 52.1)	ondansetron	56.0	(53.3, 58.7)
7	lidocaine	42.5	(40.8, 44.1)	polyethylene glycol 3350	40.7	(38.0, 43.4)	insulin lispro	47.7	(44.6, 50.8)	heparin	47.8	(45.1, 50.5)
8	dexamethasone	40.1	(38.5, 41.7)	docusate	35.1	(32.5, 37.7)	dexamethasone	44.4	(41.3, 47.5)	dexamethasone	45.9	(43.2, 48.6)
9	heparin	38.8	(37.2, 40.4)	fentanyl	30.8	(28.2, 33.4)	lidocaine	40.0	(36.9, 43.1)	insulin lispro	45.6	(42.9, 48.3)
10	insulin lispro	38.4	(36.8, 40.1)	dexamethasone	30.6	(28.1, 33.1)	heparin	39.1	(36.0, 42.2)	lidocaine	43.9	(41.2, 46.6)

Non-Hospitalized Patients

Rank	Overall(n = 19351)	Percent	95% CI	<50(n = 13121)	Percent	95% CI	50 to <65(n = 4014)	Percent	95% CI	65 or older(n = 2216)	Percent	95% CI
1	acetaminophen	8.8	(8.4, 9.2)	acetaminophen	7.4	(7.0, 7.8)	acetaminophen	10.9	(9.9, 11.9)	acetaminophen	13.4	(12.0, 14.8)
2	albuterol	7.8	(7.5, 8.2)	albuterol	6.4	(6.0, 6.8)	albuterol	10.7	(9.7, 11.7)	ACEIs/ARBs	11.6	(10.3, 12.9)
3	ondansetron	5.7	(5.3, 6.0)	ondansetron	4.4	(4.0, 4.8)	ondansetron	7.5	(6.7, 8.3)	albuterol	11.4	(10.1, 12.7)
4	azithromycin	3.7	(3.4, 4.0)	ibuprofen	3.0	(2.7, 3.3)	ACEIs/ARBs	7.3	(6.5, 8.1)	ondansetron	9.9	(8.7, 11.1)
5	ACEIs/ARBs	3.6	(3.3, 3.8)	azithromycin	2.7	(2.4, 3.0)	azithromycin	5.6	(4.9, 6.3)	atorvastatin	9.5	(8.3, 10.7)
6	benzonatate	3.1	(2.9, 3.4)	benzonatate	2.3	(2.0, 2.6)	benzonatate	5.1	(4.4, 5.8)	azithromycin	6.4	(5.4, 7.4)
7	ibuprofen	2.8	(2.6, 3.0)	fluticasone	2.2	(1.9, 2.5)	atorvastatin	5.1	(4.4, 5.8)	amlodipine	5.2	(4.3, 6.1)
8	fluticasone	2.7	(2.5, 2.9)	lidocaine	1.8	(1.6, 2.0)	metformin	4.6	(4.0, 5.2)	dexamethasone	5.1	(4.2, 6.0)
9	atorvastatin	2.5	(2.3, 2.7)	guaifenesin	1.6	(1.4, 1.8)	fluticasone	3.9	(3.3, 4.5)	aspirin	5.1	(4.2, 6.0)
10	guaifenesin	2.3	(2.1, 2.5)	codeine	1.6	(1.4, 1.8)	guaifenesin	3.8	(3.2, 4.4)	metoprolol	5.0	(4.1, 5.9)

Table 3. Medication Utilization by Baseline Comorbidity and Hospital Procedure

Positive COVID-19 Patients																																							
Percent		95% CI	Hypertension (n = 272)	Percent		95% CI	Type 2 Diabetes (n = 265)	Percent		95% CI	CGP/AsHmd (n = 175)	Percent		95% CI	Heart Disease (n = 1325)	Percent		95% CI	Chronic Kidney Disease (n = 1326)	Percent		95% CI	Cancer (n = 1354)	Percent		95% CI	Reactive Dyslexia (n = 136)	Percent		95% CI	BMJ 30 or more (n=655)	Percent		95% CI	Mechanical Ventilation (n = 66)	Percent		95% CI	EC-M50 (n = 54)
1	2.0	0.0-4.0	hypertension	1	0.0	0.0-0.0	hypertension	1	0.0	0.0-0.0	CGP/AsHmd	1	0.0	0.0-0.0	heart disease	1	0.0	0.0-0.0	chronic kidney disease	1	0.0	0.0-0.0	cancer	1	0.0	0.0-0.0	reactive dyslexia	1	0.0	0.0-0.0	bmj 30 or more	1	0.0	0.0-0.0	mechanical ventilation	1	0.0	0.0-0.0	ec-m50
2	2.0	0.0-4.0	hypertension	2	0.0	0.0-0.0	hypertension	2	0.0	0.0-0.0	CGP/AsHmd	2	0.0	0.0-0.0	heart disease	2	0.0	0.0-0.0	chronic kidney disease	2	0.0	0.0-0.0	cancer	2	0.0	0.0-0.0	reactive dyslexia	2	0.0	0.0-0.0	bmj 30 or more	2	0.0	0.0-0.0	mechanical ventilation	2	0.0	0.0-0.0	ec-m50
3	2.0	0.0-4.0	hypertension	3	0.0	0.0-0.0	hypertension	3	0.0	0.0-0.0	CGP/AsHmd	3	0.0	0.0-0.0	heart disease	3	0.0	0.0-0.0	chronic kidney disease	3	0.0	0.0-0.0	cancer	3	0.0	0.0-0.0	reactive dyslexia	3	0.0	0.0-0.0	bmj 30 or more	3	0.0	0.0-0.0	mechanical ventilation	3	0.0	0.0-0.0	ec-m50
4	2.0	0.0-4.0	hypertension	4	0.0	0.0-0.0	hypertension	4	0.0	0.0-0.0	CGP/AsHmd	4	0.0	0.0-0.0	heart disease	4	0.0	0.0-0.0	chronic kidney disease	4	0.0	0.0-0.0	cancer	4	0.0	0.0-0.0	reactive dyslexia	4	0.0	0.0-0.0	bmj 30 or more	4	0.0	0.0-0.0	mechanical ventilation	4	0.0	0.0-0.0	ec-m50
5	2.0	0.0-4.0	hypertension	5	0.0	0.0-0.0	hypertension	5	0.0	0.0-0.0	CGP/AsHmd	5	0.0	0.0-0.0	heart disease	5	0.0	0.0-0.0	chronic kidney disease	5	0.0	0.0-0.0	cancer	5	0.0	0.0-0.0	reactive dyslexia	5	0.0	0.0-0.0	bmj 30 or more	5	0.0	0.0-0.0	mechanical ventilation	5	0.0	0.0-0.0	ec-m50
6	2.0	0.0-4.0	hypertension	6	0.0	0.0-0.0	hypertension	6	0.0	0.0-0.0	CGP/AsHmd	6	0.0	0.0-0.0	heart disease	6	0.0	0.0-0.0	chronic kidney disease	6	0.0	0.0-0.0	cancer	6	0.0	0.0-0.0	reactive dyslexia	6	0.0	0.0-0.0	bmj 30 or more	6	0.0	0.0-0.0	mechanical ventilation	6	0.0	0.0-0.0	ec-m50
7	2.0	0.0-4.0	hypertension	7	0.0	0.0-0.0	hypertension	7	0.0	0.0-0.0	CGP/AsHmd	7	0.0	0.0-0.0	heart disease	7	0.0	0.0-0.0	chronic kidney disease	7	0.0	0.0-0.0	cancer	7	0.0	0.0-0.0	reactive dyslexia	7	0.0	0.0-0.0	bmj 30 or more	7	0.0	0.0-0.0	mechanical ventilation	7	0.0	0.0-0.0	ec-m50
8	2.0	0.0-4.0	hypertension	8	0.0	0.0-0.0	hypertension	8	0.0	0.0-0.0	CGP/AsHmd	8	0.0	0.0-0.0	heart disease	8	0.0	0.0-0.0	chronic kidney disease	8	0.0	0.0-0.0	cancer	8	0.0	0.0-0.0	reactive dyslexia	8	0.0	0.0-0.0	bmj 30 or more	8	0.0	0.0-0.0	mechanical ventilation	8	0.0	0.0-0.0	ec-m50
9	2.0	0.0-4.0	hypertension	9	0.0	0.0-0.0	hypertension	9	0.0	0.0-0.0	CGP/AsHmd	9	0.0	0.0-0.0	heart disease	9	0.0	0.0-0.0	chronic kidney disease	9	0.0	0.0-0.0	cancer	9	0.0	0.0-0.0	reactive dyslexia	9	0.0	0.0-0.0	bmj 30 or more	9	0.0	0.0-0.0	mechanical ventilation	9	0.0	0.0-0.0	ec-m50
10	2.0	0.0-4.0	hypertension	10	0.0	0.0-0.0	hypertension	10	0.0	0.0-0.0	CGP/AsHmd																												
Hospitalized Patients																																							
Percent		95% CI	Hypertension (n = 1897)	Percent		95% CI	Type 2 Diabetes (n = 1310)	Percent		95% CI	CGP/AsHmd (n = 597)	Percent		95% CI	Heart Disease (n = 830)	Percent		95% CI	Chronic Kidney Disease (n = 778)	Percent		95% CI	Cancer (n = 471)	Percent		95% CI	Reactive Dyslexia (n = 144)	Percent		95% CI	BMJ 30 or more (n=645)	Percent		95% CI	Mechanical Ventilation (n = 66)	Percent		95% CI	EC-M50 (n = 54)
1	2.0	0.0-4.0	hypertension	1	0.0	0.0-0.0	hypertension	1	0.0	0.0-0.0	CGP/AsHmd	1	0.0	0.0-0.0	heart disease	1	0.0	0.0-0.0	chronic kidney disease	1	0.0	0.0-0.0	cancer	1	0.0	0.0-0.0	reactive dyslexia	1	0.0	0.0-0.0	bmj 30 or more	1	0.0	0.0-0.0	mechanical ventilation	1	0.0	0.0-0.0	ec-m50
2	2.0	0.0-4.0	hypertension	2	0.0	0.0-0.0	hypertension	2	0.0	0.0-0.0	CGP/AsHmd	2	0.0	0.0-0.0	heart disease	2	0.0	0.0-0.0	chronic kidney disease	2	0.0	0.0-0.0	cancer	2	0.0	0.0-0.0	reactive dyslexia	2	0.0	0.0-0.0	bmj 30 or more	2	0.0	0.0-0.0	mechanical ventilation	2	0.0	0.0-0.0	ec-m50
3	2.0	0.0-4.0	hypertension	3	0.0	0.0-0.0	hypertension	3	0.0	0.0-0.0	CGP/AsHmd	3	0.0	0.0-0.0	heart disease	3	0.0	0.0-0.0	chronic kidney disease	3	0.0	0.0-0.0	cancer	3	0.0	0.0-0.0	reactive dyslexia	3	0.0	0.0-0.0	bmj 30 or more	3	0.0	0.0-0.0	mechanical ventilation	3	0.0	0.0-0.0	ec-m50
4	2.0	0.0-4.0	hypertension	4	0.0	0.0-0.0	hypertension	4	0.0	0.0-0.0	CGP/AsHmd	4	0.0	0.0-0.0	heart disease	4	0.0	0.0-0.0	chronic kidney disease	4	0.0	0.0-0.0	cancer	4	0.0	0.0-0.0	reactive dyslexia	4	0.0	0.0-0.0	bmj 30 or more	4	0.0	0.0-0.0	mechanical ventilation	4	0.0	0.0-0.0	ec-m50
5	2.0	0.0-4.0	hypertension	5	0.0	0.0-0.0	hypertension	5	0.0	0.0-0.0	CGP/AsHmd	5	0.0	0.0-0.0	heart disease	5	0.0	0.0-0.0	chronic kidney disease	5	0.0	0.0-0.0	cancer	5	0.0	0.0-0.0	reactive dyslexia	5	0.0	0.0-0.0	bmj 30 or more	5	0.0	0.0-0.0	mechanical ventilation	5	0.0	0.0-0.0	ec-m50
6	2.0	0.0-4.0	hypertension	6	0.0	0.0-0.0	hypertension	6	0.0	0.0-0.0	CGP/AsHmd	6	0.0	0.0-0.0	heart disease	6	0.0	0.0-0.0	chronic kidney disease	6	0.0	0.0-0.0	cancer	6	0.0	0.0-0.0	reactive dyslexia	6	0.0	0.0-0.0	bmj 30 or more	6	0.0	0.0-0.0	mechanical ventilation	6	0.0	0.0-0.0	ec-m50
7	2.0	0.0-4.0	hypertension	7	0.0	0.0-0.0	hypertension	7	0.0	0.0-0.0	CGP/AsHmd	7	0.0	0.0-0.0	heart disease	7	0.0	0.0-0.0	chronic kidney disease	7	0.0	0.0-0.0	cancer	7	0.0	0.0-0.0	reactive dyslexia	7	0.0	0.0-0.0	bmj 30 or more	7	0.0	0.0-0.0	mechanical ventilation	7	0.0	0.0-0.0	ec-m50
8	2.0	0.0-4.0	hypertension	8	0.0	0.0-0.0	hypertension	8	0.0	0.0-0.0	CGP/AsHmd	8	0.0	0.0-0.0	heart disease	8	0.0	0.0-0.0	chronic kidney disease	8	0.0	0.0-0.0	cancer	8	0.0	0.0-0.0	reactive dyslexia	8	0.0	0.0-0.0	bmj 30 or more	8	0.0	0.0-0.0	mechanical ventilation	8	0.0	0.0-0.0	ec-m50
9	2.0	0.0-4.0	hypertension	9	0.0	0.0-0.0	hypertension	9	0.0	0.0-0.0	CGP/AsHmd	9	0.0	0.0-0.0	heart disease	9	0.0	0.0-0.0	chronic kidney disease	9	0.0	0.0-0.0	cancer	9	0.0	0.0-0.0	reactive dyslexia	9	0.0	0.0-0.0	bmj 30 or more	9	0.0	0.0-0.0	mechanical ventilation	9	0.0	0.0-0.0	ec-m50
10	2.0	0.0-4.0	hypertension	10	0.0	0.0-0.0	hypertension	10	0.0	0.0-0.0	CGP/AsHmd																												
Non-Hospitalized Patients																																							
Percent		95% CI	Hypertension (n = 2503)	Percent		95% CI	Type 2 Diabetes (n = 1427)	Percent		95% CI	CGP/AsHmd (n = 1458)	Percent		95% CI	Heart Disease (n = 670)	Percent		95% CI	Chronic Kidney Disease (n = 548)	Percent		95% CI	Cancer (n = 524)	Percent		95% CI	Reactive Dyslexia (n = 46)	Percent		95% CI	BMJ 30 or more (n=677)	Percent		95% CI	Mechanical Ventilation (n = 6)	Percent		95% CI	EC-M50 (n = 6)
1	2.0	0.0-4.0	hypertension	1	0.0	0.0-0.0	hypertension	1	0.0	0.0-0.0	CGP/AsHmd	1	0.0	0.0-0.0	heart disease	1	0.0	0.0-0.0	chronic kidney disease	1	0.0	0.0-0.0	cancer	1	0.0	0.0-0.0	reactive dyslexia	1	0.0	0.0-0.0	bmj 30 or more	1	0.0	0.0-0.0	mechanical ventilation	1	0.0	0.0-0.0	ec-m50
2	2.0	0.0-4.0	hypertension	2	0.0	0.0-0.0	hypertension	2	0.0	0.0-0.0	CGP/AsHmd	2	0.0	0.0-0.0	heart disease	2	0.0	0.0-0.0	chronic kidney disease	2	0.0	0.0-0.0	cancer	2	0.0	0.0-0.0	reactive dyslexia	2	0.0	0.0-0.0	bmj 30 or more	2	0.0	0.0-0.0	mechanical ventilation	2	0.0	0.0-0.0	ec-m50
3	2.0	0.0-4.0	hypertension	3	0.0	0.0-0.0	hypertension	3	0.0	0.0-0.0	CGP/AsHmd	3	0.0	0.0-0.0	heart disease	3	0.0	0.0-0.0	chronic kidney disease	3	0.0	0.0-0.0	cancer	3	0.0	0.0-0.0	reactive dyslexia	3	0.0	0.0-0.0	bmj 30 or more	3	0.0	0.0-0.0	mechanical ventilation	3	0.0	0.0-0.0	ec-m50
4	2.0	0.0-4.0	hypertension	4	0.0	0.0-0.0	hypertension	4	0.0	0.0-0.0	CGP/AsHmd	4	0.0	0.0-0.0	heart disease	4	0.0	0.0-0.0	chronic kidney disease	4	0.0	0.0-0.0	cancer	4	0.0	0.0-0.0	reactive dyslexia	4	0.0	0.0-0.0	bmj 30 or more	4	0.0	0.0-0.0	mechanical ventilation	4	0.0	0.0-0.0	ec-m50
5	2.0	0.0-4.0	hypertension	5	0.0	0.0-0.0	hypertension	5	0.0	0.0-0.0	CGP/AsHmd	5	0.0	0.0-0.0	heart disease	5	0.0	0.0-0.0	chronic kidney disease	5	0.0	0.0-0.0	cancer	5	0.0	0.0-0.0	reactive dyslexia	5	0.0	0.0-0.0	bmj 30 or more	5	0.0	0.0-0.0	mechanical ventilation	5	0.0	0.0-0.0	ec-m50
6	2.0	0.0-4.0	hypertension	6	0.0	0.0-0.0	hypertension	6	0.0	0.0-0.0	CGP/AsHmd	6	0.0	0.0-0.0	heart disease	6	0.0	0.0-0.0	chronic kidney disease	6	0.0	0.0-0.0	cancer	6	0.0	0.0-0.0	reactive dyslexia	6	0.0	0.0-0.0	bmj 30 or more	6	0.0	0.0-0.0	mechanical ventilation	6	0.0	0.0-0.0	ec-m50
7	2.0	0.0-4.0	hypertension	7	0.0	0.0-0.0	hypertension	7	0.0	0.0-0.0	CGP/AsHmd	7	0.0	0.0-0.0	heart disease	7	0.0	0.0-0.0	chronic kidney disease	7	0.0	0.0-0.0	cancer	7	0.0	0.0-0.0	reactive dyslexia	7	0.0	0.0-0.0	bmj 30 or more	7	0.0	0.0-0.0	mechanical ventilation	7	0.0	0.0-0.0	ec-m50
8	2.0	0.0-4.0	hypertension	8	0.0	0.0-0.0	hypertension	8	0.0	0.0-0.0	CGP/AsHmd	8	0.0	0.0-0.0	heart disease	8	0.0	0.0-0.0	chronic kidney disease	8	0.0	0.0-0.0	cancer	8	0.0	0.0-0.0	reactive dyslexia	8	0.0	0.0-0.0	bmj 30 or more	8	0.0	0.0-0.0	mechanical ventilation	8	0.0	0.0-0.0	ec-m50
9	2.0	0.0-4.0	hypertension	9	0.0	0.0-0.0	hypertension	9	0.0	0.0-0.0	CGP/AsHmd	9	0.0	0.0-0.0	heart disease	9	0.0	0.0-0.0	chronic kidney disease	9	0.0	0.0-0.0	cancer	9	0.0	0.0-0.0	reactive dyslexia	9	0.0	0.0-0.0	bmj 30 or more	9	0.0	0.0-0.0	mechanical ventilation	9	0.0	0.0-0.0	ec-m50
10	2.0	0.0-4.0	hypertension	10	0.0	0.0-0.0	hypertension	10	0.0	0.0-0.0	CGP/AsHmd																												

Table 4. Medication Utilization by Month

Positive COVID-19 Patients																											
Rank	March (n = 553)	Percent	95% CI	April (n = 881)	Percent	95% CI	May (n = 707)	Percent	95% CI	June (n = 1930)	Percent	95% CI	July (n = 3765)	Percent	95% CI	August (n = 1943)	Percent	95% CI	September (n = 1074)	Percent	95% CI	October (n = 1004)	Percent	95% CI	November (n = 1044)	Percent	95% CI
1	acetaminophen	22.06	(18.60, 25.52)	acetaminophen	29.17	(26.16, 32.18)	acetaminophen	39.18	(35.58, 42.78)	acetaminophen	27.41	(25.42, 29.40)	acetaminophen	22.07	(20.74, 23.40)	acetaminophen	27.48	(25.49, 29.47)	acetaminophen	29.05	(26.33, 31.77)	acetaminophen	23.71	(21.68, 25.94)	acetaminophen	15.79	(14.57, 17.01)
2	albuterol	19.89	(16.56, 23.22)	albuterol	20.77	(18.09, 23.45)	ondansetron	23.20	(20.08, 26.32)	ondansetron	17.41	(15.70, 19.10)	albuterol	14.42	(13.30, 15.54)	ondansetron	18.79	(17.05, 20.53)	ondansetron	16.34	(16.02, 20.66)	ondansetron	16.04	(13.77, 18.33)	enoxaparin	10.76	(9.73, 11.79)
3	azithromycin	16.09	(13.02, 19.16)	ondansetron	18.50	(15.93, 21.07)	enoxaparin	23.20	(20.08, 26.32)	albuterol	16.99	(15.31, 18.67)	ondansetron	13.89	(12.78, 15.00)	albuterol	16.01	(14.38, 17.64)	albuterol	17.60	(15.32, 19.88)	albuterol	15.34	(13.11, 17.57)	ondansetron	10.29	(9.28, 11.30)
4	ondansetron	13.56	(10.76, 16.42)	enoxaparin	16.35	(13.90, 18.80)	albuterol	22.91	(19.81, 26.01)	enoxaparin	14.15	(12.59, 15.71)	enoxaparin	11.21	(10.20, 12.22)	enoxaparin	14.46	(12.90, 16.02)	lidocaine	15.27	(13.12, 17.42)	enoxaparin	10.76	(8.84, 12.68)	albuterol	9.86	(8.87, 10.85)
5	guaifenesin	11.39	(8.74, 14.04)	sennosides, USP	15.21	(12.84, 17.58)	sennosides, USP	22.35	(19.27, 25.43)	sennosides, USP	10.98	(9.58, 12.38)	lidocaine	9.06	(8.14, 9.98)	sennosides, USP	12.92	(11.43, 14.41)	enoxaparin	13.59	(11.54, 15.64)	polyethylene glycol 3350	10.56	(8.66, 12.46)	remdesivir	9.37	(8.40, 10.34)
6	enoxaparin	11.21	(8.57, 13.85)	azithromycin	14.30	(11.99, 16.61)	lidocaine	17.68	(14.86, 20.50)	lidocaine	10.88	(9.49, 12.27)	sennosides, USP	8.71	(7.81, 9.61)	polyethylene glycol 3350	12.09	(10.64, 13.54)	sennosides, USP	12.85	(10.85, 14.85)	lidocaine	10.46	(8.56, 12.36)	polyethylene glycol 3350	9.11	(8.15, 10.07)
7	polyethylene glycol 3350	10.85	(8.25, 13.45)	polyethylene glycol 3350	13.85	(11.57, 16.13)	polyethylene glycol 3350	18.27	(13.54, 19.00)	polyethylene glycol 3350	9.33	(8.03, 10.63)	dexamethasone	8.29	(7.41, 9.17)	lidocaine	11.84	(10.40, 13.28)	dexamethasone	12.20	(10.24, 14.16)	sennosides, USP	10.16	(8.29, 12.03)	dexamethasone	8.99	(8.04, 9.94)
8	hydroxychloroquine	9.95	(7.45, 12.45)	heparin	12.03	(9.88, 14.18)	heparin	15.70	(13.01, 18.39)	insulin lispro	9.82	(7.74, 10.30)	insulin lispro	8.07	(7.20, 8.94)	dexamethasone	11.07	(9.87, 12.47)	polyethylene glycol 3350	12.01	(10.06, 13.96)	dexamethasone	10.06	(8.20, 11.92)	sennosides, USP	8.62	(7.68, 9.56)
9	ceftriaxone	9.76	(7.25, 12.24)	ceftriaxone	12.03	(9.88, 14.18)	fentanyl	14.85	(12.22, 17.48)	ipratropium	8.60	(7.35, 9.85)	polyethylene glycol 3350	7.97	(7.10, 8.84)	heparin	9.32	(8.03, 10.61)	heparin	9.99	(7.83, 11.35)	metolone	8.37	(6.65, 10.09)	lidocaine	6.30	(5.45, 7.11)
10	sennosides, USP	9.40	(6.96, 11.84)	furosemide	11.12	(9.04, 13.20)	ascorbic acid	13.58	(11.05, 16.11)	heparin	8.50	(7.26, 9.74)	ACEIs/ARBs	7.30	(6.47, 8.13)	insulin lispro	6.96	(7.69, 10.23)	docusate	9.50	(7.74, 11.26)	remdesivir	7.47	(5.84, 9.10)	heparin	6.19	(5.39, 6.99)
Hospitalized Patients																											
Rank	March (n = 109)	Percent	95% CI	April (n = 217)	Percent	95% CI	May (n = 244)	Percent	95% CI	June (n = 373)	Percent	95% CI	July (n = 589)	Percent	95% CI	August (n = 407)	Percent	95% CI	September (n = 245)	Percent	95% CI	October (n = 192)	Percent	95% CI	November (n = 208)	Percent	95% CI
1	acetaminophen	86.24	(79.70, 92.78)	acetaminophen	89.40	(85.28, 93.52)	acetaminophen	86.07	(81.76, 90.44)	acetaminophen	88.47	(85.22, 91.72)	acetaminophen	89.64	(87.17, 92.11)	acetaminophen	88.70	(85.62, 91.78)	acetaminophen	91.02	(87.42, 94.62)	acetaminophen	87.56	(82.79, 92.21)	acetaminophen	88.94	(84.65, 93.23)
2	enoxaparin	55.05	(45.61, 64.49)	enoxaparin	63.13	(56.67, 69.59)	enoxaparin	63.52	(57.45, 69.59)	enoxaparin	69.44	(64.75, 74.13)	enoxaparin	66.04	(62.21, 69.87)	enoxaparin	62.90	(58.19, 67.61)	ondansetron	59.59	(53.41, 65.77)	ondansetron	59.38	(52.39, 66.37)	ondansetron	62.02	(55.39, 68.65)
3	albuterol	55.05	(45.61, 64.49)	ondansetron	60.37	(53.83, 66.91)	sennosides, USP	60.25	(54.08, 66.42)	ondansetron	60.27	(56.31, 64.23)	ondansetron	60.27	(56.31, 64.23)	ondansetron	61.92	(57.19, 66.65)	enoxaparin	53.88	(47.61, 60.15)	polyethylene glycol 3350	52.08	(44.97, 59.19)	enoxaparin	61.06	(54.39, 67.73)
4	polyethylene glycol 3350	52.29	(42.81, 61.77)	albuterol	52.05	(43.79, 58.31)	albuterol	56.57	(51.52, 61.62)	albuterol	56.57	(51.52, 61.62)	albuterol	54.16	(50.13, 58.19)	sennosides, USP	54.79	(49.94, 59.64)	lidocaine	51.41	(45.14, 57.72)	enoxaparin	51.04	(43.92, 58.16)	polyethylene glycol 3350	56.71	(49.86, 63.56)
5	azithromycin	52.29	(42.81, 61.77)	sennosides, USP	59.45	(52.88, 66.02)	ondansetron	49.59	(43.29, 55.89)	sennosides, USP	52.82	(47.74, 57.90)	sennosides, USP	52.29	(48.25, 56.33)	polyethylene glycol 3350	52.09	(47.22, 56.96)	sennosides, USP	49.39	(43.10, 55.68)	sennosides, USP	49.48	(42.36, 56.60)	remdesivir	55.29	(48.49, 62.09)
6	ondansetron	49.54	(40.05, 59.03)	polyethylene glycol 3350	53.46	(46.79, 60.13)	polyethylene glycol 3350	44.67	(38.40, 50.94)	lidocaine	45.58	(40.51, 50.65)	polyethylene glycol 3350	46.35	(42.31, 50.39)	albuterol	46.93	(42.07, 51.79)	polyethylene glycol 3350	46.94	(40.66, 53.22)	albuterol	47.40	(40.29, 54.51)	sennosides, USP	52.88	(46.06, 59.70)
7	ceftriaxone	47.71	(38.23, 57.19)	heparin	47.93	(41.25, 54.61)	heparin	43.44	(37.19, 49.69)	polyethylene glycol 3350	44.77	(39.71, 49.83)	insulin lispro	46.35	(42.31, 50.39)	lidocaine	45.21	(40.36, 50.06)	albuterol	45.71	(39.44, 51.98)	dexamethasone	43.75	(36.69, 50.81)	albuterol	52.40	(45.57, 59.23)
8	guaifenesin	45.87	(36.41, 55.33)	ceftriaxone	46.54	(39.87, 53.21)	lidocaine	40.98	(34.78, 47.18)	insulin lispro	43.70	(38.65, 48.75)	lidocaine	43.97	(39.95, 47.99)	dexamethasone	43.98	(39.14, 48.82)	dexamethasone	42.04	(35.83, 48.25)	lidocaine	42.19	(35.16, 49.22)	dexamethasone	47.12	(40.36, 53.88)
9	sennosides, USP	43.12	(33.72, 52.52)	furosemide	43.78	(37.14, 50.42)	vancomycin	38.52	(32.38, 44.66)	ipratropium	40.75	(35.79, 45.75)	dexamethasone	43.12	(39.11, 47.13)	heparin	39.31	(34.55, 44.07)	heparin	37.55	(31.46, 43.64)	metolone	42.19	(35.16, 49.22)	lidocaine	39.42	(32.74, 46.10)
10	hydroxychloroquine	42.20	(32.82, 51.58)	azithromycin	40.53	(33.98, 47.12)	fentanyl	38.11	(31.99, 44.23)	heparin	40.21	(35.22, 45.20)	ceftriaxone	37.69	(33.77, 41.61)	insulin lispro	38.13	(33.59, 43.07)	glucagon	36.73	(30.66, 42.80)	remdesivir	35.54	(31.61, 40.47)	heparin	37.50	(30.88, 44.12)
Non-Hospitalized Patients																											
Rank	March (n = 444)	Percent	95% CI	April (n = 664)	Percent	95% CI	May (n = 463)	Percent	95% CI	June (n = 1557)	Percent	95% CI	July (n = 3176)	Percent	95% CI	August (n = 1536)	Percent	95% CI	September (n = 829)	Percent	95% CI	October (n = 812)	Percent	95% CI	November (n = 836)	Percent	95% CI
1	albuterol	11.26	(8.31, 14.21)	acetaminophen	9.49	(7.26, 11.72)	acetaminophen	14.47	(11.26, 17.68)	acetaminophen	12.78	(11.12, 14.44)	acetaminophen	9.54	(8.52, 10.56)	acetaminophen	11.26	(9.68, 12.84)	acetaminophen	10.74	(8.63, 12.85)	acetaminophen	8.62	(6.89, 10.55)	albuterol	2.87	(1.74, 4.00)
2	azithromycin	7.21	(4.80, 9.62)	albuterol	7.83	(5.78, 9.88)	ondansetron	9.29	(6.64, 11.94)	albuterol	7.51	(6.20, 8.82)	albuterol	7.05	(6.16, 7.94)	albuterol	7.81	(6.47, 9.15)	albuterol	9.29	(7.31, 11.27)	albuterol	7.76	(5.92, 9.60)	acetaminophen	2.03	(1.07, 2.99)
3	acetaminophen	6.31	(4.04, 8.58)	azithromycin	5.72	(3.95, 7.49)	albuterol	7.56	(5.15, 9.97)	ondansetron	6.68	(5.44, 7.92)	ondansetron	5.29	(4.51, 6.07)	ondansetron	7.36	(6.05, 8.67)	ondansetron	6.15	(4.51, 7.79)	ondansetron	5.79	(4.18, 7.40)	benzonatate	1.44	(0.63, 2.25)
4	ondansetron	4.73	(2.75, 6.71)	ACEIs/ARBs	4.97	(3.31, 6.63)	lidocaine	3.40	(3.36, 7.46)	ACEIs/ARBs	4.11	(3.12, 5.10)	ACEIs/ARBs	3.84	(3.17, 4.51)	ibuprofen	3.97	(2.79, 4.95)	fluticasone	4.83	(3.19, 6.29)	azithromycin	3.13	(2.09, 4.57)	ondansetron	1.32	(0.58, 2.06)
5	ACEIs/ARBs	4.50	(2.57, 6.43)	ondansetron	4.82	(3.19, 6.45)	ACEIs/ARBs	5.18	(3.29, 7.20)	ibuprofen	3.79	(2.79, 4.87)	azithromycin	3.65	(3.00, 4.30)	ACEIs/ARBs	3.71	(2.76, 4.66)	lidocaine	4.58	(3.15, 6.01)	ibuprofen	3.08	(1.89, 4.27)	guaifenesin	1.08	(0.38, 1.78)
6	benzonatate	3.83	(2.04, 5.62)	atorvastatin	3.77	(2.32, 5.22)	azithromycin	4.32	(2.46, 6.18)	azithromycin	3.53	(2.61, 4.45)	ibuprofen	3.05	(2.45, 3.65)	fluticasone	3.19	(2.31, 4.07)	atorvastatin	3.62	(2.35, 4.89)	lidocaine	2.96	(1.79, 4.13)	azithromycin	0.96	(0.30, 1.62)
7	codeine	3.83	(2.04, 5.62)	levofloxacine	3.46	(2.07, 4.85)	ibuprofen	3.46	(1.79, 5.13)	metformin	3.34	(2.45, 4.23)	fluticasone	2.83	(2.25, 3.41)	lidocaine	2.99	(2.14, 3.84)	benzonatate	3.50	(2.25, 4.75)	fluticasone	2.34	(1.30, 3.38)	fluticasone	0.96	(0.30, 1.62)
8	fluticasone	3.15	(1.52, 4.78)	fluticasone	3.16	(1.83, 4.49)	atorvastatin	3.46	(1.79, 5.13)	fluticasone	2.76	(1.95, 3.57)	lidocaine	2.58	(2.03, 3.13)	atorvastatin	2.99	(2.14, 3.84)	ibuprofen	3.38	(2.15, 4.61)	fluticasone	2.09	(1.10, 3.08)	codeine	0.96	(0.30, 1.62)
9	atorvastatin	3.15	(1.52, 4.78)	benzonatate	3.16	(1.83, 4.49)	metformin	3.46	(1.79, 5.13)	benzonatate	2.70	(1.89, 3.51)	benzonatate	2.30	(1.78, 2.82)	benzonatate	2.80	(1.97, 3.63)	dexamethasone	3.38	(2.15, 4.61)	dexamethasone	2.09	(1.10, 3.08)	ibuprofen	0.84	(0.22, 1.46)
10	guaifenesin	2.93	(1.36, 4.50)	guaifenesin	3.01	(1.71, 4.31)	fluticasone	3.24	(1.62, 4.86)	lidocaine	2.57	(1.78, 3.36)	atorvastatin	2.17	(1.66, 2.68)	dexamethasone	2.34	(1.58, 3.10)	guaifenesin	2.90	(1.76, 4.04)	ACEIs/ARBs	1.85	(0.92, 2.78)	lidocaine	0.84	(0.22, 1.46)